Arrowhead Pharmaceuticals, Inc. — Cyborg Score 7/10
Strong
Biotechnology / RNA Therapeutics
Strategic Profile
The company received regulatory approval for REDEMPLO in familial chylomicronemia syndrome in three different countries and launched its first commercial product in the U.S. Arrowhead received a $200 million upfront payment from Novartis and is eligible to receive development, regulatory, and sales milestone payments of up to $2 billion with tiered royalties on commercial sales up to the low double digits. The company has demonstrated significant revenue growth with a 3-year revenue growth rate of 39%.
Cyborg Score Rationale
Arrowhead reported a significant turnaround with a net income of $30.8 million in Q1 FY2026, compared to a net loss of $173.1 million in Q1 FY2025. The company strengthened its balance sheet with $1.33 billion of recent transactions and reported $917M cash & investments. Strong pipeline depth with multiple clinical programs offsets commercial-stage execution risk.
Top Insights
REDEMPLO marks Arrowhead's first FDA-approved medicine, representing a major milestone as the company transitions into commercial-stage
The company continued to grow its cardiometabolic portfolio with encouraging early results from obesity programs
Plozasiran was granted FDA Breakthrough Therapy designation for severe hypertriglyceridemia with top-line SHASTA readouts expected in Q3 2026
Arrowhead expanded market presence with approvals in Canada and China while raising $1.33 billion through strategic transactions including payments from Novartis and Sarepta
Named Competitors
Onpattro — RNAi therapeutic for hereditary transthyretin amyloidosis
Leqvio — Antisense oligonucleotide for cardiovascular disease
WVE programs — RNA therapeutics for neurological and genetic disorders
Recent Developments
(February 2026) Announced fiscal 2026 first quarter results ended December 31, 2025 with $264M revenue and $30.8M net income
(January 2026) Chinese NMPA approved REDEMPLO for familial chylomicronemia syndrome and Health Canada issued Notice of Compliance
(January 2026) Initiated Phase 1/2a clinical trial of ARO-DIMER-PA for atherosclerotic cardiovascular disease due to mixed hyperlipidemia
(November 2025) FDA approved REDEMPLO as adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome
Open the full interactive Arrowhead Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.